A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results for " Raltegravir "

media.product.imagealternatetextformat.details

Raltegravir EP Impurity D

N° de SZ CAT:SZ-R009004
Número CAS1064706-98-4
Mol.F.C18H19FN4O6
Peso Molecular406.4
Status de FaturaIn Stock

Nome Químico: [[2-[4-[[(4-fluorophenyl)methyl]carbamoyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl]propan-2-yl]amino]oxoacetic acid (as per EP) ; 2-[(2-{4-[(4-Fluorobenzyl)carbamoyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl}propan-2-yl)amino]-2-oxoacetic acid (as per USP)

Sinônimo: Raltegravir Oxalyl Analog (USP)

Shipping Temperature: Ambient

HSN Code: 38229010

Country of Origin: India

Sorrisos: O=C(O)C(NC(C)(C1=NC(C(NCC2=CC=C(F)C=C2)=O)=C(O)C(N1C)=O)C)=O

Raltegravir EP Impurity D is chemically [[2-[4-[[(4-fluorophenyl)methyl]carbamoyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl]propan-2-yl]amino]oxoacetic acid (as per EP) ; 2-[(2-{4-[(4-Fluorobenzyl)carbamoyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl}propan-2-yl)amino]-2-oxoacetic acid (as per USP) . It is also known as Raltegravir Oxalyl Analog (USP). Raltegravir EP Impurity D is supplied with detailed characterization data compliant with regulatory guideline. Raltegravir EP Impurity D can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Raltegravir.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new development or finding in product specification without further noticed.